Safety and Effectiveness of the Genous Endothelial Progenitor Cell-Capture Stent: Follow-Up to 5 Years

• Main Author: Pereira-da-Silva, T
• Publication Date: 2013
• Other Authors: Bernardes, T, Cacela, D, Fiarresga, A, Sousa, L, Patrício, L, Cruz Ferreira, R
• Format: Article
• Language: eng
• Source: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
• Download full: http://hdl.handle.net/10400.17/1599
• topic: HSM CAR; Acute Coronary Syndrome/pathology; Acute Coronary Syndrome/therapy; Coronary Restenosis/epidemiology; Coronary Thrombosis/epidemiology; Endothelial Progenitor Cells/pathology; Follow-Up Studies; Longitudinal Studies; Myocardial Infarction/epidemiology; Percutaneous Coronary Intervention/instrumentation; Percutaneous Coronary Intervention/methods; Proportional Hazards Models; Stents*/adverse effects; Retrospective Studies; Risk Factors

AIMS: To evaluate the long-term clinical outcomes following percutaneous coronary intervention (PCI) with the Genous stent in an unselected population. METHODS: All patients admitted to a single center who underwent PCI using the GS exclusively, between May 2006 and May 2012, were enrolled, and a clinical follow-up of up to 60 months was carried out. The primary endpoint of major adverse cardiac event (MACE) rate was defined as the composite of cardiac death, acute myocardial infarction (AMI), and target lesion revascularization (TLR). RESULTS: Of the 450 patients included (75.1% male; 65.5 ± 11.7 years), 28.4% were diabetic and acute coronary syndrome was the reason for PCI in 76.4%. Angioplasty was performed in 524 lesions using 597 Genous stents, with angiographic success in 97.1%. At a median of 36 months of follow-up (range, 1-75 months), MACE, AMI, TLR, stent restenosis (SR), and stent thrombosis (ST) rates were 15.6%, 8.4%, 4.4%, 3.8%, and 2.2%, respectively. Between 12 and 24 months, the TLR, SR, and ST rates practically stabilized, up to 60 months. Bifurcation lesions were independently associated with MACE, TLR, and SR. CONCLUSION: This is the first study reporting clinical results with the Genous stent up to 60 months. The Genous stent was safe and effective in the long-term, in an unselected population.